Mobile phones in research and treatment: Ethical guidelines and future directions

Adrian Carter, Jacki Liddle, Wayne Hall, Helen Chenery

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Mobile phones and other remote monitoring devices, collectively referred to as "mHealth," promise to transform the treatment of a range of conditions, including movement disorders, such as Parkinson's disease. In this viewpoint paper, we use Parkinson's disease as an example, although most considerations discussed below are valid for a wide variety of conditions. The ability to easily collect vast arrays of personal data over long periods will give clinicians and researchers unique insights into disease treatment and progression. These capabilities also pose new ethical challenges that health care professionals will need to manage if this promise is to be realized with minimal risk of harm. These challenges include privacy protection when anonymity is not always possible, minimization of third-party uses of mHealth data, informing patients of complex risks when obtaining consent, managing data in ways that maximize benefit while minimizing the potential for disclosure to third parties, careful communication of clinically relevant information gleaned via mHealth technologies, and rigorous evaluation and regulation of mHealth products before widespread use. Given the complex array of symptoms and differences in comfort and literacy with technology, it is likely that these solutions will need to be individualized. It is therefore critical that developers of mHealth apps engage with patients throughout the development process to ensure that the technology meets their needs. These challenges will be best met through early and ongoing engagement with patients and other relevant stakeholders.

Original languageEnglish
Pages (from-to)e95
JournalJMIR mHealth and uHealth
Volume3
Issue number4
DOIs
Publication statusPublished - 16 Oct 2015

Fingerprint

Cell Phones
Telemedicine
Guidelines
Research
Technology
Parkinson Disease
Therapeutics
Patient Participation
Aptitude
Privacy
Movement Disorders
Disclosure
Disease Progression
Communication
Research Personnel
Direction compound
Delivery of Health Care
Equipment and Supplies

Cite this

Carter, Adrian ; Liddle, Jacki ; Hall, Wayne ; Chenery, Helen. / Mobile phones in research and treatment : Ethical guidelines and future directions. In: JMIR mHealth and uHealth. 2015 ; Vol. 3, No. 4. pp. e95.
@article{d9fb3247e2f14e138b6b3515ebd93807,
title = "Mobile phones in research and treatment: Ethical guidelines and future directions",
abstract = "Mobile phones and other remote monitoring devices, collectively referred to as {"}mHealth,{"} promise to transform the treatment of a range of conditions, including movement disorders, such as Parkinson's disease. In this viewpoint paper, we use Parkinson's disease as an example, although most considerations discussed below are valid for a wide variety of conditions. The ability to easily collect vast arrays of personal data over long periods will give clinicians and researchers unique insights into disease treatment and progression. These capabilities also pose new ethical challenges that health care professionals will need to manage if this promise is to be realized with minimal risk of harm. These challenges include privacy protection when anonymity is not always possible, minimization of third-party uses of mHealth data, informing patients of complex risks when obtaining consent, managing data in ways that maximize benefit while minimizing the potential for disclosure to third parties, careful communication of clinically relevant information gleaned via mHealth technologies, and rigorous evaluation and regulation of mHealth products before widespread use. Given the complex array of symptoms and differences in comfort and literacy with technology, it is likely that these solutions will need to be individualized. It is therefore critical that developers of mHealth apps engage with patients throughout the development process to ensure that the technology meets their needs. These challenges will be best met through early and ongoing engagement with patients and other relevant stakeholders.",
author = "Adrian Carter and Jacki Liddle and Wayne Hall and Helen Chenery",
year = "2015",
month = "10",
day = "16",
doi = "10.2196/mhealth.4538",
language = "English",
volume = "3",
pages = "e95",
journal = "JMIR Mhealth Uhealth",
issn = "2291-5222",
publisher = "JMIR Publications",
number = "4",

}

Mobile phones in research and treatment : Ethical guidelines and future directions. / Carter, Adrian; Liddle, Jacki; Hall, Wayne; Chenery, Helen.

In: JMIR mHealth and uHealth, Vol. 3, No. 4, 16.10.2015, p. e95.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Mobile phones in research and treatment

T2 - Ethical guidelines and future directions

AU - Carter, Adrian

AU - Liddle, Jacki

AU - Hall, Wayne

AU - Chenery, Helen

PY - 2015/10/16

Y1 - 2015/10/16

N2 - Mobile phones and other remote monitoring devices, collectively referred to as "mHealth," promise to transform the treatment of a range of conditions, including movement disorders, such as Parkinson's disease. In this viewpoint paper, we use Parkinson's disease as an example, although most considerations discussed below are valid for a wide variety of conditions. The ability to easily collect vast arrays of personal data over long periods will give clinicians and researchers unique insights into disease treatment and progression. These capabilities also pose new ethical challenges that health care professionals will need to manage if this promise is to be realized with minimal risk of harm. These challenges include privacy protection when anonymity is not always possible, minimization of third-party uses of mHealth data, informing patients of complex risks when obtaining consent, managing data in ways that maximize benefit while minimizing the potential for disclosure to third parties, careful communication of clinically relevant information gleaned via mHealth technologies, and rigorous evaluation and regulation of mHealth products before widespread use. Given the complex array of symptoms and differences in comfort and literacy with technology, it is likely that these solutions will need to be individualized. It is therefore critical that developers of mHealth apps engage with patients throughout the development process to ensure that the technology meets their needs. These challenges will be best met through early and ongoing engagement with patients and other relevant stakeholders.

AB - Mobile phones and other remote monitoring devices, collectively referred to as "mHealth," promise to transform the treatment of a range of conditions, including movement disorders, such as Parkinson's disease. In this viewpoint paper, we use Parkinson's disease as an example, although most considerations discussed below are valid for a wide variety of conditions. The ability to easily collect vast arrays of personal data over long periods will give clinicians and researchers unique insights into disease treatment and progression. These capabilities also pose new ethical challenges that health care professionals will need to manage if this promise is to be realized with minimal risk of harm. These challenges include privacy protection when anonymity is not always possible, minimization of third-party uses of mHealth data, informing patients of complex risks when obtaining consent, managing data in ways that maximize benefit while minimizing the potential for disclosure to third parties, careful communication of clinically relevant information gleaned via mHealth technologies, and rigorous evaluation and regulation of mHealth products before widespread use. Given the complex array of symptoms and differences in comfort and literacy with technology, it is likely that these solutions will need to be individualized. It is therefore critical that developers of mHealth apps engage with patients throughout the development process to ensure that the technology meets their needs. These challenges will be best met through early and ongoing engagement with patients and other relevant stakeholders.

U2 - 10.2196/mhealth.4538

DO - 10.2196/mhealth.4538

M3 - Article

VL - 3

SP - e95

JO - JMIR Mhealth Uhealth

JF - JMIR Mhealth Uhealth

SN - 2291-5222

IS - 4

ER -